DELAWARE: The State of Delaware Department of Health and Social Services (DHSS), the government agency responsible for regulating the medical use of cannabis in Delaware, has executed the state’s cannabis seed-to-sale tracking and patient registry contract with BioTrackTHC.
Delaware’s stated goals for the Medical Marijuana Program include, “protect the people of Delaware by minimizing the risk of theft and diversion of marijuana to unregistered individuals,” and, “regulate the production and sale of medical grade marijuana to registered individuals.” In pursuit of those goals, DHSS in 2016, issued a Request for Proposals for the Delaware Enterprise Consolidated Cannabis Control System, their designation for an integrated statewide seed-to-sale cannabis tracking and patient registry system.
“Our sincerest thanks to DHSS for choosing Team BioTrack,” said Patrick Vo, CEO of BioTrackTHC. “DHSS has been wonderful to work with throughout the contracting process, and we look forward to partnering with them to provide the tools and data they need to continue overseeing the industry and protecting their patients.”
The implementation of an integrated seed-to-sale tracking and patient registry system will enable the state to keep close tabs on the activity of the Medical Marijuana Program. Designated state officials will be able to view compassion center data—including plant
s counts and usable inventory, lab results, transportation, and point-of-sale data—to perform periodic audits and ensure compliance. Additionally, the patient registry portion of the system will improve patient accessibility to the Program by automating the patient application process and decreasing application processing times.
BioTrackTHC currently has live seed-to-sale government traceability systems in Washington; New Mexico; Illinois; Hawaii; New York; and the city of Arcata, California.